A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.

NCT00605345 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia

Interventions

DRUG: Darbepoetin alfa
DRUG: methoxy polyethylene glycol-epoetin beta [Mircera]

Sponsor

Hoffmann-La Roche